Integrate multiple modes of biology from a single sample in a single experiment to provide transformative insights into health and disease.
Discover our new software tool for exploring 6-base analysis.
Current technologies are unable to reliably resolve both genetic and epigenetic sequences at low sample input and miss important information. biomodal’s duet multiomics solution evoC gives you access to the 6-base genome – all four canonical bases and distinguishes 5‑methylcytosine (5mC) and 5‑hydroxymethylcytosine (5hmC) – from a single 5ng DNA sample, in a single experiment, with high accuracy.
Combined epigenetic and genetic analysis in a single sequencing run lets you access the most critical information from your DNA samples.
Better characterise liquid biopsy and genomic DNA samples of early stage cancer for diagnostic and therapy development.
Combined data reveals the role of methylation in neurodegeneration.
Pinpoint epigenetic changes that determine patterns of disease and health throughout a lifespan.
Improved DNA-based diagnostics with the ability to see disease-relevant changes from low input samples
Detect minute epigenetic changes to better understand maternal and foetal health.
A true 6-base genome that distinguishes 5mC and 5hmC together with all four canonical bases to measure multiple modes of biology
Assess all four canonical bases plus modified cytosine
CAMBRIDGE, England and SAN DIEGO—February 23, 2026—biomodal, an omics-based life sciences technology and analytics company, today announced at the AGBT 2026 General Meeting that biomodal’s
Dr. Sophie Kirschner, Associate Director, Translational Medicine, Early Oncology at AstraZeneca will present data using biomodal’s 6-base multiomics sequencing solution, duet evoC.
Distinguishing 5mC and 5hmC, enabled through duet evoC and the 6-base genome, delivered an AUC of 0.95 for stage I colorectal cancer from liquid biopsy, improving the earlier detection of stage I colorectal cancer from cfDNA samples!
We can help you reveal new data and multimodal insights from your research.
